Abion CEO Youngki Shin Purchases 720,000 Shares on the Open Market

CEO Youngki Shin of Abion purchased 720,054 shares of the company on the open market between July 24 and July 28.

According to Abion on July 28, this purchase reflects the CEO's commitment to responsible management and his intention to enhance the company's value, grounded in confidence in the company's core pipeline.

Abion's non-small cell lung cancer drug candidate 'Vavamekip (ABN401)' has demonstrated development potential as a first-line treatment. In the global Phase 2 clinical trial results released at the American Society of Clinical Oncology (ASCO) 2026, the drug achieved an objective response rate of 55% and a median duration of response of 14.5 months. These results indicate an antitumor efficacy comparable to existing approved drugs. The company is also accelerating business advancement based on its next-generation antibody-interferon beta conjugate (iRAC) platform.

The company plans to continue with additional stock purchases by management and pursue policies to enhance shareholder value. This recent stock purchase also actively reflects shareholder feedback obtained at the company's recent investor relations (IR) session and shareholder meetings.

An Abion representative said, "The current share price is undervalued and does not fully reflect the value and growth potential of our core new drug pipeline and antibody platform business. We will continue our efforts to increase corporate value, fueled by our confidence in the success of new drugs such as Vavamekip and iRAC."

This content was produced with the assistance of AI translation services.